Myeloid cell-targeted therapies for solid tumours
Myeloid cells are the most abundant immune components of the tumour microenvironment,
where they have a variety of functions, ranging from immunosuppressive to …
where they have a variety of functions, ranging from immunosuppressive to …
[HTML][HTML] Tumor microenvironment and cellular senescence: Understanding therapeutic resistance and harnessing strategies
H Liu, H Zhao, Y Sun - Seminars in Cancer Biology, 2022 - Elsevier
The tumor microenvironment (TME) is a major contributor to cancer malignancy including
development of therapeutic resistance, a process mediated in part through intercellular …
development of therapeutic resistance, a process mediated in part through intercellular …
The effect of acute exercise on circulating immune cells in newly diagnosed breast cancer patients
T Koivula, S Lempiäinen, P Rinne, JH Rannikko… - Scientific Reports, 2023 - nature.com
The role of exercise in cancer prevention and control is increasingly recognized, and based
on preclinical studies, it is hypothesized that mobilization of leukocytes plays an important …
on preclinical studies, it is hypothesized that mobilization of leukocytes plays an important …
Lymph node lymphatic endothelial cells as multifaceted gatekeepers in the immune system
Single-cell technologies have recently allowed the identification of multiple lymphatic
endothelial cell (LEC) subsets in subcapsular, paracortical, medullary, and other lymph …
endothelial cell (LEC) subsets in subcapsular, paracortical, medullary, and other lymph …
Immune cells as messengers from the CNS to the periphery: The role of the meningeal lymphatic system in immune cell migration from the CNS
In recent decades there has been a large focus on understanding the mechanisms of
peripheral immune cell infiltration into the central nervous system (CNS) in …
peripheral immune cell infiltration into the central nervous system (CNS) in …
Systemic blockade of clever-1 elicits lymphocyte activation alongside checkpoint molecule downregulation in patients with solid tumors: results from a phase I/II …
R Virtakoivu, JH Rannikko, M Viitala, F Vaura… - Clinical Cancer …, 2021 - AACR
Purpose: Macrophages are critical in driving an immunosuppressive tumor
microenvironment that counteracts the efficacy of T-cell–targeting therapies. Thus, agents …
microenvironment that counteracts the efficacy of T-cell–targeting therapies. Thus, agents …
[HTML][HTML] Myeloid checkpoints for cancer immunotherapy
Y Qian, T Yang, H Liang, M Deng - Chinese Journal of Cancer …, 2022 - ncbi.nlm.nih.gov
Myeloid checkpoints are receptors on the myeloid cell surface which can mediate inhibitory
signals to modulate anti-tumor immune activities. They can either inhibit cellular …
signals to modulate anti-tumor immune activities. They can either inhibit cellular …
Structure and immune function of afferent lymphatics and their mechanistic contribution to dendritic cell and T cell trafficking
J Arasa, V Collado-Diaz, C Halin - Cells, 2021 - mdpi.com
Afferent lymphatic vessels (LVs) mediate the transport of antigen and leukocytes to draining
lymph nodes (dLNs), thereby serving as immunologic communication highways between …
lymph nodes (dLNs), thereby serving as immunologic communication highways between …
The development of a human Brucella mucosal vaccine: What should be considered?
T Tian, Y Zhu, J Shi, K Shang, Z Yin, H Shi, Y He… - Life Sciences, 2024 - Elsevier
Brucellosis is a chronic infectious disease that is zoonotic in nature. Brucella can infect
humans through interactions with livestock, primarily via the digestive tract, respiratory tract …
humans through interactions with livestock, primarily via the digestive tract, respiratory tract …
Bexmarilimab-induced macrophage activation leads to treatment benefit in solid tumors: The phase I/II first-in-human MATINS trial
JH Rannikko, L Verlingue, M de Miguel, A Pasanen… - Cell Reports …, 2023 - cell.com
Macrophage Clever-1 contributes to impaired antigen presentation and suppression of anti-
tumor immunity. This first-in-human trial investigates the safety and tolerability of Clever-1 …
tumor immunity. This first-in-human trial investigates the safety and tolerability of Clever-1 …